Logo image of AGEN

AGENUS INC (AGEN) Stock Fundamental Analysis

NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD

2.85  -0.02 (-0.7%)

After market: 2.9696 +0.12 (+4.2%)

Fundamental Rating

1

AGEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.
In the past year AGEN has reported a negative cash flow from operations.
AGEN had negative earnings in each of the past 5 years.
In the past 5 years AGEN reported 4 times negative operating cash flow.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -100.51%, AGEN is doing worse than 76.23% of the companies in the same industry.
Industry RankSector Rank
ROA -100.51%
ROE N/A
ROIC N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

AGEN has a Gross Margin of 99.53%. This is amongst the best in the industry. AGEN outperforms 98.24% of its industry peers.
AGEN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGEN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
Compared to 1 year ago, AGEN has a worse debt to assets ratio.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -15.72, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AGEN (-15.72) is worse than 81.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.72
ROIC/WACCN/A
WACC10.22%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

2.3 Liquidity

AGEN has a Current Ratio of 0.21. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.21, AGEN is not doing good in the industry: 96.13% of the companies in the same industry are doing better.
A Quick Ratio of 0.21 indicates that AGEN may have some problems paying its short term obligations.
AGEN has a Quick ratio of 0.21. This is amonst the worse of the industry: AGEN underperforms 96.13% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.79% over the past year.
Looking at the last year, AGEN shows a very negative growth in Revenue. The Revenue has decreased by -33.81% in the last year.
The Revenue has been decreasing by -7.17% on average over the past years.
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.54%
Revenue 1Y (TTM)-33.81%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%-67.98%

3.2 Future

The Earnings Per Share is expected to grow by 13.07% on average over the next years. This is quite good.
Based on estimates for the next years, AGEN will show a very strong growth in Revenue. The Revenue will grow by 21.41% on average per year.
EPS Next Y61.51%
EPS Next 2Y32.5%
EPS Next 3Y21.06%
EPS Next 5Y13.07%
Revenue Next Year-0.85%
Revenue Next 2Y2.31%
Revenue Next 3Y1.9%
Revenue Next 5Y21.41%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

AGEN's earnings are expected to grow with 21.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.5%
EPS Next 3Y21.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGENUS INC

NASDAQ:AGEN (4/23/2025, 6:50:44 PM)

After market: 2.9696 +0.12 (+4.2%)

2.85

-0.02 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners36.51%
Inst Owner Change-0.07%
Ins Owners1.37%
Ins Owner Change0.42%
Market Cap72.13M
Analysts74.55
Price Target7.14 (150.53%)
Short Float %13.94%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.08%
Min EPS beat(2)-29.49%
Max EPS beat(2)21.32%
EPS beat(4)2
Avg EPS beat(4)-18.03%
Min EPS beat(4)-71.27%
Max EPS beat(4)21.32%
EPS beat(8)4
Avg EPS beat(8)-24.77%
EPS beat(12)7
Avg EPS beat(12)-11.69%
EPS beat(16)9
Avg EPS beat(16)-11.84%
Revenue beat(2)0
Avg Revenue beat(2)-19.77%
Min Revenue beat(2)-26.46%
Max Revenue beat(2)-13.08%
Revenue beat(4)0
Avg Revenue beat(4)-33.65%
Min Revenue beat(4)-62.51%
Max Revenue beat(4)-13.08%
Revenue beat(8)2
Avg Revenue beat(8)-7.69%
Revenue beat(12)6
Avg Revenue beat(12)10.65%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)-12.5%
EPS NQ rev (1m)14.78%
EPS NQ rev (3m)44.83%
EPS NY rev (1m)43.97%
EPS NY rev (3m)54.77%
Revenue NQ rev (1m)22.35%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-21.32%
Revenue NY rev (3m)-28.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.68
EYN/A
EPS(NY)-4.11
Fwd EYN/A
FCF(TTM)-6.28
FCFYN/A
OCF(TTM)-6.26
OCFYN/A
SpS4.09
BVpS-12.9
TBVpS-13.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.53%
FCFM N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.32%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -15.72
F-Score2
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)280.5%
Cap/Depr(5y)277.58%
Cap/Sales(3y)20.35%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.54%
EPS Next Y61.51%
EPS Next 2Y32.5%
EPS Next 3Y21.06%
EPS Next 5Y13.07%
Revenue 1Y (TTM)-33.81%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%-67.98%
Revenue Next Year-0.85%
Revenue Next 2Y2.31%
Revenue Next 3Y1.9%
Revenue Next 5Y21.41%
EBIT growth 1Y22.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.17%
EBIT Next 3Y-10.15%
EBIT Next 5Y-10.98%
FCF growth 1Y32.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.39%
OCF growth 3YN/A
OCF growth 5YN/A